| Revenue growth | Q4 revenue grew 30% YoY to 439 Cr; FY26 up 18%. |
|---|---|
| Margins | EBITDA margins improved to 28% from 26% YoY. |
| Order book | Healthy order book for CDMO and recently launched Nor-UDCA formulation. |
| Demand visibility | Strong traction in Europe and India for specialty oncology and peptides. |
| Management confidence | Confident, shifting from base APIs to high-margin specialty formulation platforms. |
Growth
Revenue grew 30% YoY in Q4; EBITDA expanded 40% YoY with margins improving to 28% through favorable operating leverage.
Outlook
Targeting global launches for high-value molecules like Nor-UDCA and Recombinant Albumin by FY28-FY29.
Risks
High reliance on lumpy licensing fees and high-stakes clinical trials; US FDA compliance at Jadhcherla remains an overhang.
Last quarter's promises, checked
Delivered
- Guided Q4 OLC block commissioning → Delivered Q4 commissioning (= BEAT)
- Guided Q4 Rotigotine US FDA submission → Delivered Q4 submission (= BEAT)
- Guided Q4 Semaglutide validation → Delivered Q4 completion (= BEAT)
Partly delivered
- Guided steady growth in API → Delivered 16% growth vs 54% in formulations (= PARTIAL)
Missed
- Guided Q4 IMPD submission for Albumin → Delayed to H1 FY27 (= MISS)
Earnings Call Transcript filed with NSE, NSE: SHILPAMED. Summary written with AI assistance from the document.
Shilpa Medicare Ltd: key numbers
- Share price
- ₹1,013.45
- Market cap
- ₹19,821 Cr
- Revenue (annual)
- ₹1,539 Cr
- Net profit (annual)
- ₹243.3 Cr
- P/E (TTM)
- 66.7×Sector 50.4×
- Promoter holding
- 40.13%+0.00% QoQ
- FII holding
- 11.39%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shilpa Medicare Ltd
All →Shilpa Medicare Share Pledge
The company's promoters reported the release of encumbrance on 30,00,000 equity shares held by them. This reduction in pledged shares signals a change in promoter leverage.
Shilpa Medicare Other Announcement
Shilpa Medicare received a 'Crisil ESG 59' rating from CRISIL ESG Ratings for FY2026. This is a routine regulatory disclosure under Regulation 30 with no financial implications.
Shilpa Medicare Business Update
Shilpa Medicare reported a USFDA surveillance inspection at its Unit VII Analytical Services Division. The inspection resulted in one procedural observation with no material impact on operations.
Shilpa Medicare Regulatory Approval
Shilpa Medicare secured final CDSCO-SEC approval for OERIS™, a world-first extended-release ondansetron injection patented until 2039. Commercial launch in India is planned upon final marketing authorization.
Shilpa Medicare Annual General Meeting
Shilpa Medicare's 39th AGM held 11 September 2026 via VC. Resolutions covered financial statement adoption, ₹0.60/share dividend, and director re-appointment.
Shilpa Medicare Insolvency Petition
NCLT Ahmedabad admitted FTF Pharma, Shilpa Medicare's subsidiary, to CIRP over a ₹2.18 Crore debt. IRP appointed with moratorium; impact on parent unquantifiable.
- Value
- ₹2.18 Cr